Sweden’s Orexo wins the launch of clinical trials to study nasal adrenaline formulation
MT Newswires 2022
|
|
|
|
|
||||
Technical analysis trends OREXO AB (PUBL)
Short-term | After half the time | Long term | |
Trends | Lower | Lower | Lower |
Development of the income statement
Sell buy |
|
Average consensus | HOLD |
Number of analysts | 1 |
Latest closing price | 19.36 SEK |
Average target price | 33.50 SEK |
Spread / Average target | 73.0% |